Abstract: Described herein is cancer biomarker, e.g., a vesicle, capture surface that includes a substrate, a first plurality of nanoparticles attached to the substrate; a plurality of bifunctional tethers, wherein a first functionality of the bifunctional tethers is attached to at least a portion of the first plurality of nanoparticles; a second plurality of nanoparticles attached to a second functionality of at least a portion of the plurality of bifunctional tethers; a capture agent attached to at least a portion of the second plurality of nanoparticles; and a plurality of polymer brush molecules attached to the surface, wherein the polymer brush molecules have a lower molecular weight than the bifunctional tethers, and wherein the polymer brush molecules reduce nonspecific binding to the surface. Also described are method of capturing cancer biomarkers such as vesicles from a liquid biopsy sample.

Abstract: The present subject matter provides urea biosensors as well as compositions, devices, and methods comprising such biosensors.

Abstract: An assay substrate including a first component comprising a sensor molecule labeled with a quantum dot, the quantum dot immobilized to an assay substrate surface with a first linker being a bi-polar linker comprising a first binding group for specific binding of the quantum dot and a second binding group for specific binding of the assay substrate surface, the sensor molecule having a specific binding site for an organic analyte, the sensor molecule labeled with the quantum dot in a position that has no effect on the organic analyte binding the specific binding site; and a second component comprising a chemical analogue of the organic analyte, the chemical analogue labeled with a fluorescent dye, the chemical analogue linked to the quantum dot with a second linker having a length exceeding Foster radius, and the chemical analogue reversibly binding the specific binding site of the sensor molecule of the first component.

Abstract: The invention relates to a method of assembling a biosensor device comprising two or more biosensor units, wherein each unit comprises one or more biosensors comprising one or more carbon nanotubes (CNTs) coated with nucleic acid and one or more sensor molecules coupled to the nucleic acid, wherein each one of the one or more sensor molecules is capable of binding to a target molecule in a sample. Each biosensor unit is capable of detecting a different target molecule in a sample, and each unit comprises one or more biosensors each capable of detecting the same target molecule. The invention further relates to biosensor devices and methods for detecting target molecules in a sample using the same.

Abstract: Compositions comprising fluorescent or colored dyes and methods of using the same in combination with divalent metal salts to analyze samples are disclosed.

Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.

Abstract: A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.

Abstract: A device comprising a modified porous membrane is provided. The modified porous membrane comprises a polymer coating grafted to a porous membrane. The device is used for analyte detection from a biological sample using an immunoassay. The device comprises a sample application zone at one end of the device for applying a biological sample comprising a target analyte; and a detection zone present at another end of the device, downstream of the sample application zone for detecting the target analyte, wherein the detection zone comprises one or more first biomolecules immobilized on a modified porous membrane having a structure of Formula (I).

Abstract: Disclosed herein are methods and assays for the detection and/or quantification of one or more proteins or substances of interest in a sample, such as a plant, human, insect, microorganism or mammalian sample.

Abstract: This invention resides in using metal complex-activated particles to bind molecules, polymers and other particles to each other, so as to produce multifunctional conjugates having controlled ratios of two or more different molecules.

Abstract: Immobilising isolated mycolic acid antigens of tuberculous mycobacterial origin or a synthetic analogue thereof on a screen-printed electrode by binding of the antigens to a self-assembled monolayer comprising a thiolated hydrophobic substance to produce immobilized mycolic acids antigens in the form of a mycolic acid antigen-containing self-assembled monolayer coating on a surface of the electrode.

Abstract: A detection reagent for comprehensively detecting an oxidized state and a glycated state of a low-density lipoprotein. While an oxidized low-density lipoprotein and a glycated low-density lipoprotein are detected with a fluolophore-labelled antibody, a lipid radical is detected with a fluorescent nitroxide 2,2,6-trimethyl-4-(4-nitrobenzo[1,2,5]oxadiazol-7-ylamino)-6-pentylpiperadine-1-oxyl (NBD-Pen).

Abstract: A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.

Abstract: A method and a device for detection and quantification of various organic analytes in a liquid sample and an assay substrate for providing analyte measurements. The method is implemented by using specific interaction of organic analytes with selective binding sites immobilized on a multi-layer assay substrate with further detection of such interaction with a device based on inducing and recording the fluorescence of the substrate for bio-chemical, genetic and environmental analyses.

Abstract: Provided in the present invention are a magnetic nanosphere coated with modified cardiolipin, and manufacturing method thereof. The magnetic nanosphere coated with modified cardiolipin comprises a modified cardiolipin, a biotin derivative, and a streptavidin magnetic bead. The modified cardiolipin is coupled to the biotin derivative via an —NH—CO structure. The streptavidin magnetic bead is a magnetic nanosphere coupled to streptavidin, and the biotin derivative is coupled to the streptavidin.

Abstract: The invention provides a method that gives direct information about the intervention of a potential drug on the secondary structure distribution of a targetbiomolecule, i.e., for a disease with misfolded protein, such as neurodegenerative diseases in a complex body fluid. The secondary structural change is monitored by vibrational spectroscopy. The method can be applied for prescreening of drug candidates for targeting of specific biomolecules. The effect of the drug on the secondary structure distribution is monitored label-free in real time and provides thereby direct information about the efficacy of the potential drug.

Abstract: Disclosed herein are embodiments of nanohoop compounds and conjugates thereof that can be used myriad biological applications. The nanohoop compounds described herein can exhibit beneficial properties that are useful in biotechnology, such as a fluorescent tag, probe, or label.

Abstract: Provided are an additive and a surface treatment agent capable of suppressing agglutination of latex particles contained in a reagent for a latex agglutination reaction during storage of the reagent although a synthetic polymer is contained as an active component. An additive is to be added to latex particles used in a reagent for a latex agglutination reaction. The latex particles have not been subjected to blocking treatment. The additive includes a polymer containing more than 60% by mass and 99% by mass or less of hydrophilic repeating units (A) relative to all repeating units and 1% by mass or more and less than 40% by mass of hydrophobic repeating units (B) relative to all repeating units, and having a weight average molecular weight of 3,000 or more.

Abstract: The invention relates to methods for the diagnosis of ischemia or ischemic tissue damage, methods for predicting the progression of ischemia in a patient having suffered an ischemic event, for determining the prognosis of a patient having suffered an ischemic event and for determining the risk that a patient suffering from stable coronary disease suffers a recurrent ischemic event based on the detection of the levels of glycosylated Apo J. The invention relates as well to a method for the determination of glycosylated Apo J in a sample.

Abstract: The present invention relates to a method for measuring the cholesterol uptake capacity of lipoproteins. The present invention also relates to a reagent kit for measuring the cholesterol uptake capacity of lipoproteins. The present invention further relates to a tagged cholesterol which can be used in the method and the reagent kit.